Authors: Wakabayashi, K.; Yoshida, K.¹; Leung, P. S. C.¹; Moritoki, Y.¹; Yang, G.-X.¹; Tsuneyama, K.²; Lian, Z.-X.¹; Hibi, T.³; Ansari, A. A.⁴; Wicker, L. S.⁵; Ridgway, W. M.⁶; Coppel, R. L.⁷; Mackay, I. R.⁸; Gershwin, M. E.¹

Source: Clinical & Experimental Immunology, Volume 155, Number 3, March 2009 , pp. 577-586(10)

Publisher: Wiley-Blackwell

Abstract:

Summary

Our laboratory has suggested that loss of tolerance to pyruvate dehydrogenase (PDC-E2) leads to an anti-mitochondrial antibody response and autoimmune cholangitis, similar to human primary biliary cirrhosis (PBC). We have suggested that this loss of tolerance can be induced either via chemical xenobiotic immunization or exposure to select bacteria. Our work has also highlighted the importance of genetic susceptibility. Using the non-obese diabetic (NOD) congenic strain 1101 (hereafter referred to as NOD.1101 mice), which has chromosome 3 regions from B6 introgressed onto a NOD background, we exposed animals to 2-octynoic acid (2OA) coupled to bovine serum albumin (BSA). 2OA has been demonstrated previously by a quantitative structural activity relationship to react as well as or better than lipoic acid to anti-mitochondrial antibodies. We demonstrate herein that NOD.1101 mice immunized with 2OA-BSA, but not with BSA alone, develop high titre anti-mitochondrial antibodies and histological features, including portal infiltrates enriched in CD8⁺ cells and liver granulomas, similar to human PBC. We believe this model will allow the rigorous dissection of early immunogenetic cause of biliary damage.

Keywords: AMAs; autoimmune cholangitis; NOD.1101 mice; PBC; xenobiotic agents

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2249.2008.03837.x

Affiliations: 1: Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA, USA, 2: Department of Pathology (I), University of Toyama School of Medicine, Toyama, Japan, 3: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 4: Department of Pathology, Emory University School of Medicine, 5: Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK, 6: Division of Immunology, University of Cincinnati School of Medicine, Cininnati, OH, USA, 7: Department of Microbiology, and 8: Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

Publication date: 2009-03-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Microbiology ,  Allergy & Immunology
• By this author: Wakabayashi, K. ;  Yoshida, K. ;  Leung, P. S. C. ;  Moritoki, Y. ;  Yang, G.-X. ;  Tsuneyama, K. ;  Lian, Z.-X. ;  Hibi, T. ;  Ansari, A. A. ;  Wicker, L. S. ;  Ridgway, W. M. ;  Coppel, R. L. ;  Mackay, I. R. ;  Gershwin, M. E.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers